These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26598056)

  • 1. Practical Approaches to Immunotherapy in the Clinic.
    Agarwala SS
    Semin Oncol; 2015 Dec; 42 Suppl 3():S20-7. PubMed ID: 26598056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions.
    Atkins M
    Semin Oncol; 2015 Dec; 42 Suppl 3():S12-9. PubMed ID: 26598055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Pagès C; Baroudjian B; Lebbé C
    Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Emerging Perspectives on Immunotherapy for Melanoma.
    Daud A
    Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in immunotherapy for melanoma.
    Redman JM; Gibney GT; Atkins MB
    BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
    Teng F; Kong L; Meng X; Yang J; Yu J
    Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A; Larkin J
    Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 15. [Side effects of Modern Immunotherapy and How to Solve Them in the Clinics].
    Lakomý R; Poprach A
    Klin Onkol; 2015; 28 Suppl 4():4S103-14. PubMed ID: 26647898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of immunotherapy.
    Suzuki S; Ishida T; Yoshikawa K; Ueda R
    Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death 1 immune checkpoint inhibitors.
    Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
    Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
    Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
    Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
    Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.